Everything begins with a cell.
Cells are the fundamental units of life. They produce energy, communicate and adapt. Cellular health is the study of how these essential processes are maintained—and how they change across the lifespan.
Elevate is informed by Longevity Life Sciences, an Australian company advancing cellular health through science.
Life, at its most fundamental.
Every tissue and organ depends on the health of its cells. Within them, connected systems manage energy, maintenance, signalling and responses to stress.
These systems do not operate in isolation. Cellular health is therefore best understood as an interconnected foundation for how the body functions and adapts over time.
Ageing is more than the passage of time.
Scientific advances have made it possible to observe biological changes associated with ageing at cellular and molecular levels. Researchers use frameworks such as the hallmarks of ageing to organise these interconnected processes and study their influence on health and function.
The hallmarks include changes in genomic stability, telomeres, epigenetic regulation, protein maintenance, autophagy, nutrient sensing, mitochondrial function, cellular senescence, stem-cell activity, intercellular communication, inflammation and the microbiome.
This framework does not reduce ageing to one mechanism or promise that it can be reversed. It gives researchers a shared language for asking better questions.
The hallmarks of ageing are an evolving scientific framework describing interconnected biological processes associated with ageing. Adapted from López-Otín et al., Cell, 2013 and subsequent updates.
More function in the years we have.
Healthy ageing is concerned with maintaining the abilities that support wellbeing across later life. As populations age, research is increasingly focused not only on lifespan, but on healthspan: the years lived with function, independence and vitality.
Cellular-health science contributes to this broader field by examining the biological systems that sit beneath health and function.
What is NAD+?
Nicotinamide adenine dinucleotide (NAD+) is found in every cell. It acts as an essential coenzyme in cellular energy production and as a substrate for enzymes in cellular energy production and stress responses, supporting metabolism and mitochondrial function.
Research suggests that NAD+ availability may change with age and across tissues. The causes and implications are complex, and human research continues to develop. This has made NAD+ metabolism an important area of contemporary cellular-health science.
How the body maintains NAD+
The body makes NAD+ through several metabolic pathways. One of these is the salvage pathway, which recycles nicotinamide into NAD+ through a series of enzyme-led steps.
Nicotinamide mononucleotide, or NMN, is an intermediate in this pathway. It can be converted into NAD+ by nicotinamide mononucleotide adenylyltransferase enzymes.
Understanding this pathway helps explain why NMN has become a focus of research. It does not, by itself, establish a clinical benefit; that requires well-designed human studies using relevant products, doses and outcomes.
An emerging human evidence base.
NMN is a naturally occurring molecule and one of several NAD+ precursors studied in cellular and healthy-ageing research.
In December 2025, the Therapeutic Goods Administration (TGA) added NMN as a Permissible Ingredient for use in Listed Medicines in Australia, after reviewing the safety and quality dossier.
Longevity Life Sciences, in partnership with the University of Sydney are currently undergoing a clinical trial to understand the impacts of NMN on humans.
From assumption to observation.
Biomarkers allow researchers to observe aspects of biology that cannot be understood from symptoms or perception alone. In cellular-health research, they may be used to measure baseline status, study change over time and explore why individuals respond differently.
Longevity Life Sciences is interested in a measured approach:
Measure
Establish relevant baseline biomarkers.
Understand
Interpret results within the person’s broader health context.
Personalise
Use evidence to inform an appropriate strategy.
Reassess
Track change and refine where clinically meaningful.
Testing should support informed care—not create certainty where the science does not yet allow it.
advancing cellular health through science.
Longevity Life Sciences works across scientific research, clinical collaboration, regulatory pathways, proprietary ingredients, formulation technologies and biomarker platforms.
Its role is to discover, validate and translate emerging cellular-health science with the discipline required for regulated health products. Elevate brings selected outcomes of that work into daily life.
Australia’s therapeutic-goods framework provides a valuable setting for this work. CellVive NMN® was the ingredient sponsored for inclusion in the Therapeutic Goods Administration’s permissible-ingredients determination, enabling its use in Australian listed medicines subject to defined conditions.
The ingredient is only the beginning.
The performance and quality of a formulation depend on more than the name of its active ingredient. Identity, purity, dose, stability, excipients, delivery system, manufacturing controls and finished-product testing all matter.
Elevate considers these elements together. It is a formulation philosophy grounded in precision: include what has a clear purpose, substantiate what can be said and continue testing what remains to be established.
Designed with stability and delivery in mind.
PlexoZome® is a liposomal technology that uses phospholipid-based structures to encapsulate selected active ingredients. Liposomes share structural characteristics with biological membranes and are widely studied as delivery systems.
In Elevate CellVive NMN® Advance, PlexoZome® forms part of a product-specific formulation designed with ingredient stability and delivery in mind. Product-specific pharmacokinetic research is planned to examine how the finished formulation behaves in humans.
Until those results are available and appropriately reviewed, Elevate will not make comparative claims about superior absorption, bioavailability or cellular uptake.
Research designed to answer useful questions.
Longevity Life Sciences is supporting research to deepen understanding of NMN, NAD+ biology and cellular-health outcomes. This includes a University of Sydney randomised controlled trial examining CellVive NMN® at 500 mg daily over 12 weeks in healthy adults aged 40 to 65, alongside product-specific pharmacokinetic work for Elevate CellVive NMN® Advance.
The program is designed to build evidence progressively—from safety and exposure to biomarkers and functional outcomes—without reaching beyond what the data can support.
CellVive NMN® in each daily dose
University of Sydney randomised controlled trial, in progress
Age range of the healthy adults in the trial
Listed on the Australian Register of Therapeutic Goods
Cellular-health science is evolving. Our responsibility is to follow the evidence with curiosity, communicate its limits clearly and translate progress with care.
Because a life elevated should begin with a standard worthy of it.